The investigational hemophilia drug emicizumab cut the bleed rate by 87% in patients with resistance to standard therapy versus those receiving another treatment.
Seattle Genetics and Takeda Pharmaceutical Company announced positive results from the Phase III ECHELON-1 clinical trial in previously untreated advanced classical Hodgkin lymphoma.
European regulators recommended the approval of Aveo Pharmaceuticals Inc.’s drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market.
European regulators recommended approval of a second copy of AbbVie’s rheumatoid arthritis drug Humira, the world’s top-selling medicine.
Merck KGaA won a key recommendation to become an entrant to the oral MS drug market in Europe, six years after its first attempt to launch the cladribine pill failed.
A European Medicines Agency (EMA) panel recommended approving Novartis’s Kisqali drug, bolstering the Swiss drugmaker’s bid to challenge rival Pfizer’s Ibrance against tough-to-treat breast cancer.
Shares of pain-relief company Cara Therapeutics were up more than 16 percent after the company grabbed the Breakthrough Therapy Designation for its chronic kidney disease treatment CR845.
bluebird bio’s interim data for its Phase III gene therapy LentiGlobin trial showed promising results in reducing a patient’s need for blood transfusions after one month after treatment, but the data also raised some concerns.
The U.S. FDA approved Genentech’s Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection for the treatment of adults with certain blood cancers.
Mylan NV shareholders voted against the generic drugmaker’s executive pay policy but re-elected the board at its 2017 annual meeting despite a shareholder campaign in the wake of a scandal over high prices for its EpiPen emergency allergy treatment.